Denosumab (Xgeva)
Jump to navigation
Jump to search
Also known as Prolia.
General information
Class/mechanism: Human IgG2 monoclonal antibody that inhibits RANK ligand (RANKL). RANKL promotes the formation, function, and survival of osteoclasts, which are responsible for bone resorption.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Denosumab (Xgeva) patient drug information (Chemocare)[5]
- Brief patient counseling information can be found on page 13 of the Denosumab (Xgeva) package insert[1]
- Denosumab (Xgeva) patient drug information (UpToDate)[6]